secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001641172-25-007944
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Interpace Biosciences restructures after Medicare LCD ends PancraGEN coverage
-----------------------------------------------------------------------------

- Medicare LCD L39365 ends PancraGEN reimbursement as of April 24, 2025; no specimens after May 2.
- Workforce reduction announced; severance costs $0.5-0.6M in Q2 plus $0.2M in Q1 2025.
- Restructuring to cut annual cost of revenue and OpEx by $12.5-14.5M, offsetting ~1/3 of revenue loss.
- Plan substantially complete by end of Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000164117225007944/0001641172-25-007944-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000164117225007944/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-007944

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer